Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Hidradenitis Suppurativa
NCT04084665Phase 1Withdrawn
- Sponsor
- The Rockefeller University
- Start
- Jun 2020
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guselkumab in hidradenitis suppurativa (HS), sponsored by The Rockefeller University. Primary endpoints: Biomarkers at 24 weeks and Incidence of Treatment-Emergent Adverse Events at 24 weeks. Planned start Jun 2020; status: withdrawn.
02
Drugs
guselkumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04084665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084665.